09.20.13
Limerick, Pa.-based Teleflex Inc., maker of critical care and surgical devices, has introduced the new Arrow JACC (jugular axillo-subclavian central catheter) with Chlorag+ard technology. The technology received U.S. Food and Drug Administration 510(k) clearance in November 2012.
The Arrow JACC with Chlorag+ard technology is a small-french size antimicrobial and antithrombogenic catheter designed for both acute and long-term use. The Arrow JACC employs Chlorag+ard technology as a weapon against thrombosis and infection for up to 30 days, and is reportedly effective against the full spectrum of bacterial and fungal pathogens. Approximately 250,000 patients acquire catheter-related bloodstream infections each year in the United States, with oncology, diabetic, critically ill and chronically ill patients at highest risk. According to the Centers for Disease Control and Prevention, an estimated 30,000 to 62,000 patients die each year as a result of a catheter-related bloodstream infection.
“We are very excited to announce our launch of the Arrow JACC with Chlorag+ard technology,” said Benson Smith, chairman, president, and CEO of Teleflex. “This product’s innovative design offers clinicians a new and unique treatment option that further demonstrates our commitment to achieve ‘zero complications’ in vascular access. We believe the Arrow JACC represents a significant step forward in raising the standard of care for patients requiring vascular access, while equally addressing the clinical need for treatment efficiency and cost-effectiveness in our challenging healthcare environment.”
The Arrow JACC is designed specifically for use by vascular access specialists. The placing of central venous catheters by vascular access specialists is, according to Teleflex, an emerging trend within healthcare. These specialists are driving best practices, such as the use of antimicrobial catheters, ultrasound and maximal barrier precautions, to offset the high-demand and workload of physicians who have traditionally placed central catheters.
The Arrow JACC with Chlorag+ard technology is a small-french size antimicrobial and antithrombogenic catheter designed for both acute and long-term use. The Arrow JACC employs Chlorag+ard technology as a weapon against thrombosis and infection for up to 30 days, and is reportedly effective against the full spectrum of bacterial and fungal pathogens. Approximately 250,000 patients acquire catheter-related bloodstream infections each year in the United States, with oncology, diabetic, critically ill and chronically ill patients at highest risk. According to the Centers for Disease Control and Prevention, an estimated 30,000 to 62,000 patients die each year as a result of a catheter-related bloodstream infection.
“We are very excited to announce our launch of the Arrow JACC with Chlorag+ard technology,” said Benson Smith, chairman, president, and CEO of Teleflex. “This product’s innovative design offers clinicians a new and unique treatment option that further demonstrates our commitment to achieve ‘zero complications’ in vascular access. We believe the Arrow JACC represents a significant step forward in raising the standard of care for patients requiring vascular access, while equally addressing the clinical need for treatment efficiency and cost-effectiveness in our challenging healthcare environment.”
The Arrow JACC is designed specifically for use by vascular access specialists. The placing of central venous catheters by vascular access specialists is, according to Teleflex, an emerging trend within healthcare. These specialists are driving best practices, such as the use of antimicrobial catheters, ultrasound and maximal barrier precautions, to offset the high-demand and workload of physicians who have traditionally placed central catheters.